about
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's diseaseBacterial ProteasomesThe 26S proteasome is a multifaceted target for anti-cancer therapiesThe Not4 RING E3 Ligase: A Relevant Player in Cotranslational Quality ControlStructure of a Proteasome Pba1-Pba2 Complex: IMPLICATIONS FOR PROTEASOME ASSEMBLY, ACTIVATION, AND BIOLOGICAL FUNCTIONStructural insights into the conformational diversity of ClpP from Bacillus subtilisAn Archaeal Homolog of Proteasome Assembly Factor Functions as a Proteasome ActivatorMolecular architecture and assembly of the eukaryotic proteasomeLoss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of actionBlm10 protein promotes proteasomal substrate turnover by an active gating mechanismBlm10 facilitates nuclear import of proteasome core particlesProteasome assemblyThe ubiquitin proteasome system and myocardial ischemiaRegulation of proteasome activity in health and diseaseImmune and myodegenerative pathomechanisms in inclusion body myositisMolecular and cellular roles of PI31 (PSMF1) protein in regulation of proteasome function.PA28αβ: the enigmatic magic ring of the proteasome?The N-end rule pathway and regulation by proteolysisTwists and turns in ubiquitin-like protein conjugation cascades.Functional reconstitution of human eukaryotic translation initiation factor 3 (eIF3).RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair.Regulating the 20S proteasome ubiquitin-independent degradation pathway.Paradigms of protein degradation by the proteasome.Intrinsically disordered segments affect protein half-life in the cell and during evolution.Assembly of an Evolutionarily Conserved Alternative Proteasome Isoform in Human Cells.N-α-acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28β.Increased proteasome activator 28 gamma (PA28γ) levels are unspecific but correlate with disease activity in rheumatoid arthritis.A conserved F box regulatory complex controls proteasome activity in Drosophila.Deciphering preferential interactions within supramolecular protein complexes: the proteasome case.C termini of proteasomal ATPases play nonequivalent roles in cellular assembly of mammalian 26 S proteasomeMiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.Regulated protein turnover: snapshots of the proteasome in action.Ubiquitin-independent proteasomal degradation during oncogenic viral infections.Loss of Rpt5 protein interactions with the core particle and Nas2 protein causes the formation of faulty proteasomes that are inhibited by Ecm29 protein.An adenosine triphosphate-independent proteasome activator contributes to the virulence of Mycobacterium tuberculosis.Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution.Involvement of the nuclear proteasome activator PA28γ in the cellular response to DNA double-strand breaks.Proteasomes and protein conjugation across domains of life.Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat ProteinReduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
P2860
Q26749321-0D0704CC-4A88-4695-A8DE-CFDB8F2BA156Q26778726-E19A7DCE-3A49-4527-983B-C6BC73E8CD87Q26795764-32812263-EEA8-45AC-874B-00409A5435D0Q27027216-C4B7E0AF-D3D1-49CA-872D-7C6AACB93DD1Q27671782-0182F0E3-AAAC-4550-BCB9-6C0BA20C2B61Q27675546-7B4E0BC0-71D3-43BB-8B82-D083FA0ACB0FQ27677216-93F76787-7C94-44A4-BEBB-BAAC9C0E51C0Q27693890-657AE89F-240A-4A4E-9D23-E160E47F1D1AQ27930325-D77B5EBD-AD40-447F-9C5B-35EB751CF3FCQ27931319-213BF39F-5183-4DDE-8CFA-1210AB5D2BF1Q27936817-B47E9069-D105-46D4-8613-8FF1D30AEE67Q28245575-3F37B2F8-C0E6-4DCD-A28F-370172005049Q28280898-FA4C9B38-73CA-4D49-AF6D-041DA143C762Q28392708-1B4DDED8-E106-4A27-B78F-CD807FB72830Q33753870-FF3CD5D5-576D-4375-93CD-1E7A6F2F420BQ33792867-6615EADF-1AC7-4114-89C5-D33371D84F2BQ33912635-0EB10D19-380A-4253-9F94-796020D7149AQ34189152-54FF1FDF-DAB3-44F3-B218-2978C51E7E0EQ34225698-BA99BD8E-2FEA-42D9-A128-F5B8F35A2F82Q34237617-92C4B708-4B28-473A-8300-DB18E31D980BQ34290557-9D17A74A-B1BB-4AFB-9C85-8EF951EB8FE3Q34318192-7DAB9CE6-E7BE-4584-9B35-F5EC1067FD14Q34410240-A016EB97-EC71-42F5-B703-F6F7C12DE947Q34438593-E861724F-BD61-4246-982F-8F01079C0425Q34519129-C9398C0D-6FE7-4449-B25D-735BC7BBD440Q34691587-DAB159CE-88F8-4ABE-B3DE-AE2D43A812EAQ34967751-08594B84-74C6-4B6B-9BFC-C2BB4E4477BAQ35025085-8981E139-7D8D-4162-8028-4869F6189004Q35093980-678F95ED-33C8-4E2A-BAAA-A234DC12665BQ35128239-0DF3CAC2-0716-4DBC-BECB-671F28DBE65EQ35178969-F07C2F54-B5E5-43CB-A6D8-1F4B1464C0F9Q35257872-7B7671CD-FF03-4B46-B43E-68ABDA8FF88FQ35354212-296D0B41-9C31-4AD0-B4F7-A46D39F18950Q35378632-2EA0F1CE-AE40-496A-A298-28D01B6E7F1BQ35378709-73295B6D-1C95-4257-A716-D872D0743E1EQ35694579-D9DF8C78-5B8A-4812-900B-4D9235880B0EQ35737515-1771A09F-C148-40EB-BCEF-DD9A3F3A12E3Q35792807-1695E5E4-6C75-48DF-9B8B-1FDD95CBDFD5Q35843506-E8409DA8-1A7C-434C-A4E5-1912889C0407Q35874721-8C949B6B-BFE3-4044-A861-76E9EC0CB66F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proteasome activators.
@en
Proteasome activators.
@nl
type
label
Proteasome activators.
@en
Proteasome activators.
@nl
prefLabel
Proteasome activators.
@en
Proteasome activators.
@nl
P2860
P1433
P1476
Proteasome activators.
@en
P2093
Beth M Stadtmueller
Christopher P Hill
P2860
P356
10.1016/J.MOLCEL.2010.12.020
P577
2011-01-01T00:00:00Z